Michael A. Metzger - Nov 8, 2022 Form 4 Insider Report for CTI BIOPHARMA CORP (CTIC)

Role
Director
Signature
/s/ David Kirske, attorney-in-fact for Michael A. Metzger
Stock symbol
CTIC
Transactions as of
Nov 8, 2022
Transactions value $
-$424,047
Form type
4
Date filed
11/10/2022, 03:54 PM
Previous filing
Oct 7, 2022
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $24K +28.5K $0.84* 28.5K Nov 8, 2022 Direct
transaction CTIC common stock Options Exercise $63K +63K +221.05% $1.00* 91.5K Nov 8, 2022 Direct
transaction CTIC common stock Sale -$277K -50.1K -54.71% $5.53 41.4K Nov 8, 2022 Direct F1, F2
transaction CTIC common stock Sale -$209K -36.9K -89.14% $5.65 4.5K Nov 8, 2022 Direct F1, F3
transaction CTIC common stock Sale -$25.7K -4.5K -100% $5.70 0 Nov 8, 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -28.5K -100% $0.00* 0 Nov 8, 2022 Common Stock 28.5K $0.84 Direct F5
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -63K -50% $0.00 63K Nov 8, 2022 Common Stock 63K $1.00 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
F2 Reflects sales of common stock executed in multiple transactions at prices ranging from $ 5.50 to $ 5.59. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3 Reflects sales of common stock executed in multiple transactions at prices ranging from $ 5.60 to $ 5.695. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4 Reflects sales of common stock executed in multiple transactions at prices ranging from $ 5.70 to $ 5.72. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5 The shares underlying the option were fully vested on May 16, 2020, the date that is twelve months after the date of grant.
F6 The shares underlying the option were fully vested on March 11, 2021, the date that is twelve months after the date of grant.